Gilead Sciences (GILD) Receives a Buy From TD Cowen
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)
Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78
Barclays Sticks to Its Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Analyst Ratings
Gilead Sciences Analyst Ratings
Gilead Sciences (GILD) Receives a Hold From RBC Capital
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117
Gilead Sciences Analyst Ratings
What 8 Analyst Ratings Have To Say About Gilead Sciences
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)
Hold Rating on Gilead Sciences Amid Trodelvy Trial Setbacks and Future Uncertainties
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)